HER2 Circulating Tumor Cells in Gastric Cancer
The recruitment status of this study is unknown because the information has not been verified recently.
Verified June 2013 by Samsung Medical Center.
Recruitment status was Active, not recruiting
Information provided by (Responsible Party):
Won Ki Kang, Samsung Medical Center
First received: February 17, 2011
Last updated: June 12, 2013
Last verified: June 2013
The investigators propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer.
||Observational Model: Cohort
Time Perspective: Prospective
||HER2 Circulating Tumor Cells in Gastric Cancer
Biospecimen Retention: Samples Without DNA
Primary Outcome Measures:
- To survey the frequency of HER2(+) CTC in gastric cancer [ Time Frame: 24month ] [ Designated as safety issue: No ]
blood, circulating tumor cell
| Estimated Enrollment:
| Study Start Date:
| Estimated Study Completion Date:
| Primary Completion Date:
||March 2013 (Final data collection date for primary outcome measure)
We propose to survey the frequency of HER2 (+) CTC in order to lay groundwork for future clinical trials incorporating Her-2 targeted agents in gastric cancer. Blood samples will be collected from metastatic gastric cancer patients.
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
metastatic gastric cancer
- Patients older than 18 years ② Patients with localized, histologically confirmed gastric cancer ③ Informed consent form
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01299688
|Samsung Medical Center
|Seoul, Korea, Republic of |
Samsung Medical Center
||Won Ki Kang, MD
||Samsung Medical Center
No publications provided
||Won Ki Kang, Professor, Samsung Medical Center
History of Changes
|Other Study ID Numbers:
|Study First Received:
||February 17, 2011
||June 12, 2013
||Korea: Food and Drug Administration
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on August 03, 2015
Neoplastic Cells, Circulating
Digestive System Diseases
Digestive System Neoplasms
Neoplasms by Site